Lipidomics Equipment Market Research Report and Outlook by 2028

The lipidomics equipment market is anticipated to grow significantly, reaching an estimated US$ 2,662.67 million by 2028, up from US$ 1,025.38 million in 2021. This growth represents a compound annual growth rate (CAGR) of 14.7% from 2022 to 2028. The expansion of this market is primarily driven by advancements in mass spectrometry technology and the increasing applications of lipidomics within the biomedical sciences. However, the high cost of premium products poses a challenge to the growth of the lipidomics equipment market.

Lipidomics is a burgeoning area of biological science focused on the comprehensive analysis of lipids. This field encompasses the systematic quantification and identification of various lipid networks and pathways, as well as their interactions with proteins and other molecular entities. The rising demand for precise disease diagnostics, the shift towards personalized medicine, ongoing technological innovations in lipidomics, and substantial investments from both public and private sectors in research and development (R&D) are expected to propel market growth throughout the forecast period.

The lipidomics equipment market is categorized by type into targeted and untargeted lipidomics. The targeted segment is projected to dominate the market in 2021 and is expected to exhibit the highest CAGR during the forecast period. In terms of offerings, the market is divided into several categories, including MS-based lipidomics techniques, assays for lipid metabolism, lipid flux studies using heavy isotope-labeled precursors, as well as software and services. The MS-based lipidomics techniques and assays for lipid metabolism are anticipated to capture the largest market share in 2021 and are expected to grow at the fastest rate in the coming years.

When examining services, the lipidomics market is segmented into biomarker identification, bioinformatics analysis and data interpretation, molecular analysis of various lipids (Lipid Fingerprinting), semi-quantitative and quantitative analysis, and lipid flux studies. The biomarker identification segment is expected to hold the largest share in 2021 and is projected to experience the highest growth rate during the forecast period. Additionally, the market is segmented by end users, which include molecular research, cellular research, clinical research, tissue and organ research, data research, organism research, technical services and prototyping, production, and others.

In March 2022, a collaborative study involving Lipotype GmbH, Lund University, and the Twincore Centre for Experimental and Clinical Infection Research demonstrated that lipid measurements in blood could serve as predictive markers for type 2 diabetes and cardiovascular diseases. The researchers believe that lipidome analysis could become a more efficient and cost-effective diagnostic method compared to traditional assays. Similarly, in February 2022, a team from the Peking University Health Science Center conducted a liquid chromatography-mass spectrometry (LCMS)-based targeted lipidomics assay on 311 participants, showcasing the potential of lipidomics for large-scale population screening, particularly for high-risk lung cancer groups, identifying nine lipid profiles linked to early-stage lung cancer.

The biopharmaceutical sector is heavily investing in R&D, with countries like China and India generating substantial demand for lipidomics equipment due to numerous ongoing projects across various end-user industries. Major market players are establishing new R&D and innovation centers in Asia and collaborating with local entities to leverage the opportunities these regions present. For instance, Shimadzu (China) Co., Ltd. launched the China MS Center in Beijing in October 2015 to enhance its mass spectrometer market share and promote joint R&D initiatives.

Moreover, both government and private universities are actively promoting lipidomics and its applications. In 2018, the Department of Science and Technology (DST-FIST) of the Government of India partnered with Amity University to create the Amity Lipidomics Research Facility (ALRF). In August 2022, Amity University hosted a week-long training program on materials characterization, lipidomics, and proteomics techniques, sponsored by the DST under its Synergistic Training program Utilizing the Scientific and Technological Infrastructure (STUTI). Additionally, the Central Food Technological Research Institute (CSIR) established a lipidomics center in India in 2016, providing access to advanced instruments for lipid research.

Historically, the development of automated mass spectrometer solutions has primarily focused on pre- and post-analytical processes. Companies such as Shimadzu, Thermo Fisher, Tecan Group, Agilent, SCIEX, Waters, and Aurora have introduced semi-automated mass spectrometers in recent years. In 2022, Thermo Fisher launched the Cascadion SM Clinical Analyzer, a fully automated system designed to streamline clinical testing processes, currently capable of running only one vitamin D assay. The introduction of such fully automated systems paves the way for complete automation in lipidome characterization, indicating that automated lipidomics equipment is likely to become a significant trend in the market during the forecast period.

Key organizations such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Health and Medical Research Council (NHMRC), and National Institute of Standards and Technology (NIST) are among the primary and secondary sources referenced in the preparation of the lipidomics equipment market report.